Prevotella copri alleviates sarcopenia via attenuating muscle mass loss and function decline
Xiaolei Liu, Jiqiu Wu, Jingyi Tang, Zhigang Xu, Bailing Zhou, Yang Liu, Fengjuan Hu, Gongchang Zhang, Rui Cheng, Xin Xia, Yilong Chen, Hongyu Wu, Daoming Wang, Jirong Yue, Biao Dong, Jingyuan Fu, Haopeng Yu, Birong Dong - Physiology (medical)
- Orthopedics and Sports Medicine
Abstract
Background
The gut microbiome and fecal metabolites have been found to influence sarcopenia, but whether there are potential bacteria that can alleviate sarcopenia has been under‐investigated, and the molecular mechanism remains unclear.
Methods
To investigate the relationships between the gut microbiome, fecal metabolites and sarcopenia, subjects were selected from observational multi‐ethnic study conducted in Western China. Sarcopenia was diagnosed according to the criteria of the Asian Working Group for Sarcopenia 2014. The gut microbiome was profiled by shotgun metagenomic sequencing. Untargeted metabolomic analysis was performed to analyse the differences in fecal metabolites. We investigated bacterium with the greatest relative abundance difference between healthy individuals and sarcopenia patients, and the differences in metabolites associated with the bacteria, to verify its effects on muscle mass and function in a mouse model.
Results
The study included 283 participants (68.90% females, mean age: 66.66 years old) with and without sarcopenia (141 and 142 participants, respectively) and from the Han (98 participants), Zang (88 participants) and Qiang (97 participants) ethnic groups. This showed an overall reduction (15.03% vs. 20.77%, P = 0.01) of
Conclusions
The results indicated that there were lower levels of both